<DOC>
	<DOCNO>NCT00423410</DOCNO>
	<brief_summary>This study evaluate safety , pharmacokinetics ( PK ) , pharmacodynamic effect novel anti-cancer drug , EPC2407 , administer patient advanced cancer respond recur follow treatment available therapy</brief_summary>
	<brief_title>A Safety Study EPC2407 , A Anti-Cancer Drug With Vascular Disrupting Activity : In Patients With Advanced Cancer</brief_title>
	<detailed_description>This Phase I , open label , multicenter , dose-escalation , safety , pharmacokinetic , pharmacodynamic study EPC2407 administer intravenously 60 minute QDx3 schedule repeat every 21 day . Patients enrol dosed level define escalation scheme . The primary goal study design assess toxicity fix dose level accord modify Fibonacci schema .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>1 . Histologically cytologically confirm solid tumor lymphoma , progressed standard therapy , effective therapy available patient unwilling undergo therapy . 2 . Males Females least 18 year age 3 . Laboratory data specify ( accord site 's clinical laboratory range normal ) : i. Hematology : ANC &gt; 1500 cells/mm3 , platelet count &gt; 100,000 cells/mm3 Hemoglobin &gt; 9 gm/L ii . Hepatic : Direct bilirubin &lt; 1.5 X ULN ; alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 X ULN . For patient know liver metastasis liver neoplasm : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5.0 X ULN iii . Renal : serum creatinine WNL creatinine clearance &gt; 60 mL/min 4 . 12lead electrocardiogram ( ECG ) QT interval : QTc ≤ 450 msec men ≤ 470 msec woman . 5 . Estimated life expectancy least 3 month 6 . ECOG Performance Status &lt; = 1 7 . Previously treat CNS disease allow treatment complete stable 4 week . 8 . For men woman childproducing potential willingness employ appropriate contraceptive method ( include abstinence ) study 9 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return require assessment 10 . Cardiac ejection fraction ≥50 % 2D Echocardiogram &gt; institutional low limit normal 1 . Women pregnant nursing 2 . Radiotherapy chemotherapy within previous 21 day five half life prior drug ( whichever short ) . See also exclusion # 4 patient risk cardiac toxicity . Recovery Grade 1 less chemotherapyinduced toxic effect , except alopecia , require . 3 . Major surgery within last 4 week minor surgery within last 2 week 4 . Significant risk cardiac drug toxicity due following : ) Active New York Heart Association Class III IV , b ) history current congestive heart failure , c ) history myocardial infarction within last 6 month ongoing unstable angina , anthracycline exposure per exclusion # 5 . 5 . Anthracycline exposure exceed cumulative dose 360 mg/m² 6 . Known ongoing HIV , Hepatitis B Hepatitis C infection 7 . Concomitant use strong inhibitor liver microsomal enzyme CYP2C8 , CYP2C9 , CYP2C19 CYP3A4 . 8 . Participation concurrent study investigational agent device 9 . Any condition include limited major comorbidities , opinion investigator would render patient ineligible 10 . O2 Saturation pulse oximetry rest &lt; 90 % 11 . Concomitant use drug significant risk Torsades de Pointes also prohibit . Please refer drug list `` Drugs Risk Torsades de Pointes ''</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Tumor</keyword>
	<keyword>Lymphoma</keyword>
</DOC>